Lannett Co. (NYSE:LCI) was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a report issued on Tuesday, Stock Ratings Network.com reports. The firm currently has a $40.10 price target on the stock. Zacks‘ price objective would suggest a potential upside of 5.08% from the stock’s previous close. Lannett Company, Inc. (NYSE:LCI) stock opened at $38.78 in last trading session, and closed at $40.99, trading in the range of $38.50 – $41.11. The stock showed a positive weekly performance of 27.97%.
Cardiome Pharma Corp. (NASDAQ:CRME) announced that a poster titled “Medical conversion with Vernakalant on postoperative cardio-surgical patients” by Thöne, M. et al., from the Department of Cardiovascular Surgery at the Heinrich-Heine-University Düsseldorf located in Düsseldorf, Germany, was presented at the 43rd Annual Meeting of the Germany Society for Thoracic and Cardiovascular Surgery held in Freiburg February 9-12, 2014. The study was an independent, investigator-led investigation that demonstrated real-world cardioversion experience with BRINAVESS™ (vernakalant IV) in patients who developed post-cardiac surgery atrial fibrillation (AF). CARDIOME PHARMA CORP(NASDAQ:CRME) shares closed at $9.60 on last trade day. Stock 52 week range is $1.58 – $10.10. Company’s market capitalization is $119.72 million.
U.S. Food and Drug Administration declined to approve DURECT Corporation (NASDAQ:DRRX)’s post-operative pain treatment, saying the application lacked enough data to prove the drug was safe. The FDA indicated that more clinical safety studies would have to be conducted on the drug, Posidur, Durect said. The specialty pharmaceutical company said it was evaluating the issues described in the “complete response letter”, the type of letter issued by the FDA to convey that it cannot approve a drug application in its current form. DURECT Corporation (NASDAQ:DRRX) shares closed at $1.55 on last trade day, by losing -20.51%. Stock 52 week range is $0.76 – $2.69. Company’s market capitalization is $171.11 billion.
The Medicines Company (NASDAQ:MDCO) announced that its intravenous anticoagulant, cangrelor has received an unfavorable recommendation from the U.S. Food and Drug Administration’s (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC). The company is looking to get cangrelor approved for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI) and in patients requiring bridging from oral antiplatelet therapy to surgery. The FDA panel voted against approval of cangrelor for both indications. A response from the FDA on cangrelor’s marketing application is expected by Apr 30. The Medicines Company (NASDAQ:MDCO) stock opened at $28.95 in last trading session and closed at $29.28. The 52 week range of the stock is $28.00 – $41.28 and the day range was $28.00 – $29.57.